 |
 |
 |
 |
 |
 |
 |
 |
Zidovudine/Lamivudine/Abacavir (Trizivir)
Overview
- A Clinical Overview of Zidovudine/Lamivudine/Abacavir (Trizivir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Zidovudine/Lamivudine/Abacavir (Trizivir) (PDF) (October 2006)
From GlaxoSmithKline - FDA Approves Trizivir for HIV (November 15, 2000)
From U.S. Food and Drug Administration
Research
- Literature Citations for Trizivir (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Trizivir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - The End of the Line for an Induction-Maintenance Approach to HIV Treatment Involving Zidovudine/Lamivudine/Abacavir? (November 14, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - Zidovudine/Lamivudine/Abacavir May Be Appropriate for Some Treatment-Naive Patients With Low-Baseline Viral Loads (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - HIV JournalView: Induction-Maintenance With Zidovudine/Lamivudine/Abacavir (July/August 2005)
A much-maligned triple-NRTI combo gets a second look as part of a simplification strategy.
In HIV Treatment ALERTS!, from The Body PRO - A5095 and the Triple-Nucleoside Saga (January 2005)
A second look at the study that -- at the time -- appeared to doom Trizivir; part of HIV JournalView's Top 10 Research Reports of 2004.
In AIDS Treatment News, from The Body PRO - Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
In The XV International AIDS Conference, from The Body PRO - Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine - Efavirenz or Nevirapine Regimens Are More Potent Than Trizivir for Initial Therapy (September 15, 2003)
A 100-patient Spanish study confirms the findings of ACTG 5095.
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Trizivir Plus Efavirenz Potent for Naive Patients With Low CD4 Counts and High Viral Loads (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - We Want Our Trizivir! (September/October 2003)
IAS 2003 attendees defend the use of Trizivir at the presentation on ACTG 5095.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - AIDS Healthcare Foundation Asks FDA to Withdraw Approval of GSK's Antiretroviral Drug Trizivir (August 20, 2003)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - ACTG 5095: Efavirenz-Based Regimens Outperform Triple Nucleoside Combination (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Another Look at Induction Maintenance Therapy (July 14, 2003)
48-week data on Trizivir and efavirenz in treatment-naive patients.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Efavirenz-Based HAART Outperforms a Triple Nucleoside Regimen in Clinical Practice (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Is Trizivir Plus Tenofovir Effective in Patients With Possible or Proven Reverse Transcriptase Resistance? (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Trizivir Causes Lowest Triglycerides Rise in Comparison With Combivir + Nelfinavir or d4T (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Trizivir Often Successful in Treatment-Naive Patients; Resistance Testing Key for Failures (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Abandon Trizivir When It's Working Well? A Rebuttal (July 2003)
Emily J. Erbelding, M.D., says: Don't fix what ain't broke.
In Hopkins HIV Report - The Buzz: Anatomy of a Study -- Trizivir vs. Sustiva (May/June 2003)
A closer look at ACTG 5095, which examined the use of Trizivir and efavirenz in several first-line treatment regimens.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - Abacavir Arm Stopped in Clinical Trial (April 4, 2003)
In AIDS Treatment News, from AIDS Treatment News - Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here
From U.S. National Institute of Allergy and Infectious Diseases - Dear Healthcare Provider Letter From the Division of AIDS -- Concern About Trizivir Potency (Spring 2003)
Recap from Jeffrey T. Schouten, M.D., one of the A5095 study's investigators.
In STEP Perspective, from Seattle Treatment Education Project - Efficacy and Safety of AZT/3TC/ABC (Trizivir) Maintenance Treatment After First-Line Quadruple Induction Therapy; Interim 24-Week Data From AZLF3004/TRISUD (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Efficacy of Quad Therapy in Antiretroviral-Naive Adults With Very Low CD4 Cell Counts: The Tetra Study (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Shift in HIV-1 Resistance After Treatment Interruption in Patients With Virological Failure and Antiviral Effect Following Trizivir Plus Efavirenz (AZLF3003 Study) (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Trizivir Preferred Over Continued HAART in HIV-Infected Patients (March/April 2002)
TRIZAL study results; highlights from ICAAC 2002.
In Body Positive, from Body Positive - CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Switch to Trizivir Versus Continued HAART Provides Equivalent HIV-1 RNA Suppression at 48 Weeks (TRIZAL - AZL30002) (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Comparison of the Metabolic Disorders and Clinical Lipodystrophy 48 Weeks After Switching From HAART to Trizivir Versus Continued HAART (TRIZAL: AZL30002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Clinical Management
Clinical Management
  |
  |